NR1I2 and Familial prostate cancer: Conflicting results regarding the PXR status in prostate cancer tissues [26,27] prompted us to evaluate its expression by immunohistochemistry using a tissue microarray including 512 samples from 449 patients with clinically localized disease (CLC), 48 patients with castration-resistant disease (CRPC), and 15 patients with metastatic disease (MET).